Allakos Inc.
ALLK
ALLK: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
moreShow ALLK Financials
Recent trades of ALLK by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Christopher L. Jacobs House / R | Purchase $1,001 - $15,000 | Jun. 16, 2022 |
Recently reported changes by institutional investors
Quarterly net insider trading by ALLK's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis Dec. 21, 2021
-
Patent Title: Methods and compositions for treating fibrotic diseases Sep. 15, 2020
-
Patent Title: Methods and compositions for treating siglec-8 associated diseases Jan. 22, 2019
-
Patent Title: Anti-siglec-8 antibodies and methods of use thereof Jan. 17, 2017
Federal grants, loans, and purchases
Followers on ALLK's company Twitter account
Number of mentions of ALLK in WallStreetBets Daily Discussion
Recent insights relating to ALLK
Recent picks made for ALLK stock on CNBC
ETFs with the largest estimated holdings in ALLK
Flights by private jets registered to ALLK